Intel stock extends gains after report of possible U.S. government stake
On Wednesday, Mizuho (NYSE:MFG) made adjustments to its financial outlook for Fortrea (NASDAQ:FTRE), reducing the company’s price target from $10.00 to $8.00 while maintaining a Neutral rating. The stock, currently trading at $5.00, has fallen over 82% in the past year, with analyst targets ranging from $5.00 to $15.50. InvestingPro analysis shows 6 analysts have recently revised their earnings estimates upward for the upcoming period. The decision followed Fortrea’s first-quarter earnings report for 2025, which, despite surpassing earnings expectations, revealed weaker-than-anticipated booking trends. With annual revenue of $2.69 billion and a gross profit margin of 20.2%, these trends were attributed to delays in securing awards from biotech clients and a subdued demand in the clinical pharmacology sector. According to InvestingPro’s comprehensive analysis, the company maintains a ’Fair’ financial health rating despite current challenges.
Alongside the quarterly financial disclosure, Fortrea announced a significant change in its leadership. Thomas Pike, the CEO and Chairman of the Board, is set to step down from his roles. Peter Neupert, who currently serves as the Lead Independent (LON:IOG) Director, will take over as the interim CEO and Board Chair starting May 13th. While the company wasn’t profitable in the last twelve months, InvestingPro’s detailed Research Report, available with a subscription, indicates analysts expect profitability to return this year.
Mizuho’s analyst cited several factors influencing the revised price target and earnings per share estimates for the years 2025 to 2027. The analyst pointed to the unexpected earnings beat but also noted the potential challenges Fortrea may face. These include a difficult funding landscape and a volatile macroeconomic environment, which could be exacerbated by the transition in the company’s executive leadership. The company’s strong free cash flow yield and management’s aggressive share buyback program suggest potential value creation opportunities despite these challenges.
The departure of Thomas Pike marks a period of transition for Fortrea, with Peter Neupert stepping in to guide the company through its next phase. Mizuho’s reiteration of a Neutral rating reflects a cautious outlook for Fortrea as it navigates the challenges ahead, balancing the positive aspects of the earnings beat with the uncertainties presented by the current economic climate and the change in CEO.
In other recent news, Fortrea Holdings Inc. reported its first-quarter 2025 earnings, which fell significantly short of analysts’ expectations. The company announced an earnings per share (EPS) of $0.02, missing the projected $0.41, while revenue reached $651.3 million, below the anticipated $821 million. This earnings miss was accompanied by a substantial net loss of $562.9 million, primarily due to a $488.8 million goodwill impairment. Despite these setbacks, Fortrea reaffirmed its revenue guidance for 2025, targeting between $2.45 billion and $2.55 billion, and adjusted EBITDA guidance of $170 to $200 million. The company is also implementing cost reduction strategies, aiming for $150 million in savings for the year. Analysts have expressed concerns about the biotech funding environment and decision-making delays, which Fortrea’s management addressed by emphasizing ongoing cost reduction strategies. The company remains committed to improving its financial stability and maintaining its revenue and adjusted EBITDA guidance for the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.